Skip to main content

Table 1

From: Clinical and economic efficiency to reduce dose etanercept and adalimumab in patients with rheumatoid arthritis

 

BASELINE

3 months (p baseline-3m)

6 months (p 3m-6m)

INFERENCE

VAS (mm)

    

-ETN

21.00±16.63

26.50±18.56 (p = 0.048)

23.89±17.28 (p = 0.22)

p = 0.89

-ADA

30.00±20.00

38.67±18.03 (p = 0.49)

20.00±19.36 (p = 0.54)

p = 0.36

HAQ

    

-ETN

0.48±0.50

0.61±0.45 (p = 0.33)

0.49±0.40 (p = 0.34)

p = 0.67

-ADA

1.33±0.21

1.66±0.28 (p = 0.19)

1.93±0.26 (p = 0.25)

p = 0.003

DAS28

    

-ETN

2.15±0.45

2.74±0.85 (p = 0.056)

2.41±0.77 (p = 0.005)

p = 0.20

-ADA

2.13±0.47

3.85±1.07 (p = 0.97)

2.98±1.03 (p = 0.005)

p = 0.005